ScripFollowing a mutual agreement, Gilead Sciences, Inc. has waived its option to acquire Pionyr Immunotherapeutics Inc. for a pre-set price, enabling Pionyr to shop around for new opportunities as mac
ScripScrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Visus Licenses Drugs From Cella, Delive
Medtech InsightMedical Device Acquisitions The first quarter featured 24 device M&A transactions, 17 of which had disclosed values that together totaled $10.2bn, versus the fourth quarter of 2020, when 21 deals tota